Inventor · disambiguated record
William Frederick Westlin, Iii
Also filed as: WESTLIN III WILLIAM FREDERICK · WESTLIN WILLIAM F
16 granted patents·8 pending applications·655 citations·filing 1999–2020
95Inventor score
Files withCELGENE AVILOMICS RES INC10CELGENE CAR LLC5GILEAD APOLLO LLC2PRAECIS PHARM INC2SINGH JUSWINDER2
Top patents by PatentIndex Score
24 records- 0199US8609679B22,4-diaminopyrimidines useful as kinase inhibitorsCELGENE AVILOMICS RES INC·Filed 2012·Granted Dec 17, 2013·84 cites·4 claims
- 0298US8710222B22,4-disubstituted pyrimidines useful as kinase inhibitorsCELGENE AVILOMICS RES INC·Filed 2012·Granted Apr 29, 2014·52 cites·3 claims
- 0398US8450335B22,4-disubstituted pyrimidines useful as kinase inhibitorsSINGH JUSWINDER·Filed 2009·Granted May 28, 2013·130 cites·22 claims
- 0498US8338439B22,4-disubstituted pyrimidines useful as kinase inhibitorsSINGH JUSWINDER·Filed 2009·Granted Dec 25, 2012·175 cites·2 claims
- 0597US9987276B2Substituted 2,4-diaminopyrimidines as kinase inhibitorsCELGENE CAR LLC·Filed 2016·Granted Jun 5, 2018·23 cites·26 claims
- 0696US9212181B2Substituted 2,4-diaminopyrimidines as kinase inhibitorsCELGENE AVILOMICS RES INC·Filed 2012·Granted Dec 15, 2015·34 cites·42 claims
- 0795US10010548B22,4-disubstituted pyrimidines useful as kinase inhibitorsCELGENE CAR LLC·Filed 2016·Granted Jul 3, 2018·15 cites·4 claims
- 0895US9409921B22,4-disubstituted pyrimidines as kinase inhibitorsCELGENE AVILOMICS RES INC·Filed 2014·Granted Aug 9, 2016·25 cites·2 claims
- 0995US9296737B2Substituted 2,4-diaminopyrimidines as kinase inhibitorsCELGENE AVILOMICS RES INC·Filed 2012·Granted Mar 29, 2016·27 cites·23 claims
- 1094US8563568B2Besylate salt of a BTK inhibitorWITOWSKI STEVEN RICHARD·Filed 2011·Granted Oct 22, 2013·46 cites·14 claims
- 1191US9604936B2Besylate salt of a BTK inhibitorCELGENE AVILOMICS RES INC·Filed 2013·Granted Mar 28, 2017·13 cites·14 claims
- 1290US11351168B12,4-disubstituted pyrimidines useful as kinase inhibitorsCELGENE CAR LLC·Filed 2020·Granted Jun 7, 2022·2 cites·3 claims
- 1390US10828300B2Substituted 2,4-diaminopyrimidines as kinase inhibitorsCELGENE CAR LLC·Filed 2018·Granted Nov 10, 2020·3 cites·27 claims
- 1490US10596172B22,4-disubstituted pyrimidines useful as kinase inhibitorsCELGENE CAR LLC·Filed 2018·Granted Mar 24, 2020·5 cites·3 claims
- 1569US9364476B2Methods of treating a Bruton's Tyrosine Kinase disease or disorderCELGENE AVILOMICS RES INC·Filed 2012·Granted Jun 14, 2016·1 cites·26 claims
- 1662US6372719B1ανβ3 integrin antagonists in combination with chemotherapeutic agentsFiled 1999·Granted Apr 16, 2002·20 cites·13 claims
- 1760US2019381045A1Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver diseaseGILEAD APOLLO LLC·Filed 2019·Application pending·0 cites
- 1853US2018021341A1Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver diseaseGILEAD APOLLO LLC·Filed 2016·Application pending·0 cites
- 1945US2007254303A1Methods for assessing the efficacy of treatment with a glucocorticoidPRAECIS PHARM INC·Filed 2007·Application pending·0 cites
- 2045US2016287588A1Methods of treating a bruton's tyrosine kinase disease or disorderCELGENE AVILOMICS RES INC·Filed 2016·Application pending·0 cites
- 2144US2007254843A1Methods for treating bone associated diseases by the use of methionine aminopeptidase-2 inhibitorsPRAECIS PHARM INC·Filed 2007·Application pending·0 cites
- 2243US2003050250A1Alpha v beta 3 integrin antagonists in combination with chemotherapeutic agentsFiled 2001·Application pending·0 cites
- 2341US2015216865A1Methods of treating a bruton's tyrosine kinase disease or disorderCELGENE AVILOMICS RES INC·Filed 2013·Application pending·0 cites
- 2432US2017173011A1Methods of treating a bruton's tyrosine kinase disease or disorderCELGENE AVILOMICS RES INC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when William Frederick Westlin, Iii files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →